Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.33 |
| ▸ | CYP17A1 | P05093 | 1/20 | 0.33 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.33 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.33 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23634131 | 0.81 | HDAC8 (0.34) | HDAC8CYP17A1CYP3A4CYP2C9CYP2C19 | |
| SCHEMBL6976768 | 0.79 | TAAR1 (0.34) | HDAC8CYP17A1CYP3A4CYP2C9CYP2C19 | |
| SCHEMBL19475219 | 0.76 | — | — | |
| SCHEMBL24862786 | 0.75 | CNR1 (0.31) | HDAC8 | |
| SCHEMBL18622148 | 0.73 | — | — | |
| SCHEMBL23188113 | 0.71 | — | — | |
| Hydrochloric Acid SCHEMBL18641395 | 0.71 | HDAC8 (0.37) | HDAC8CYP17A1CYP3A4CYP2C9CYP2C19 | |
| SCHEMBL23668407 | 0.69 | HDAC8 (0.32) | HDAC8CYP17A1CYP3A4CYP2C9CYP2C19 | |
| SCHEMBL14977364 | 0.68 | CYP17A1 (0.32) | CYP17A1CYP3A4CYP2C9CYP2C19 | |
| SCHEMBL2652921 | 0.68 | ACLY (0.40) | CYP2C9CYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11718631-B2 | Sulphonamides and compositions thereof for treating conditions associated with NLRP activity | NOVARTIS AG (CH) | 2023-08-08 | — | — | US | disclosed |
| US-11718631-B2 | Sulphonamides and compositions thereof for treating conditions associated with NLRP activity | NOVARTIS AG (CH) | 2023-08-08 | — | — | US | disclosed |
| US-11718631-B2 | Sulphonamides and compositions thereof for treating conditions associated with NLRP activity | NOVARTIS AG (CH) | 2023-08-08 | — | — | US | disclosed |
| EP-3445749-B1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH NLRP ACTIVITY | NOVARTIS AG (CH) | 2022-12-21 | — | — | EP | disclosed |
| EP-3445749-B1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH NLRP ACTIVITY | NOVARTIS AG (CH) | 2022-12-21 | — | — | EP | disclosed |
| US-20220387397-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH NLRP ACTIVITY | NOVARTIS AG (CH) | 2022-12-08 | — | — | US | disclosed |
| US-20220340591-A1 | SULPHONAMIDES AND COMPOSITIONS THEREOF FOR TREATING CONDITIONS ASSOCIATED WITH NLRP ACTIVITY | NOVARTIS AG (CH) | 2022-10-27 | — | — | US | disclosed |
| US-11447460-B2 | Compounds and compositions for treating conditions associated with NLRP activity | NOVARTIS AG (CH) | 2022-09-20 | — | — | US | disclosed |
| EP-3697758-B1 | SULPHONAMIDES AND COMPOSITIONS THEREOF FOR TREATING CONDITIONS ASSOCIATED WITH NLRP ACTIVITY | NOVARTIS AG (CH) | 2022-07-06 | — | — | EP | disclosed |
| EP-3697758-B1 | SULPHONAMIDES AND COMPOSITIONS THEREOF FOR TREATING CONDITIONS ASSOCIATED WITH NLRP ACTIVITY | NOVARTIS AG (CH) | 2022-07-06 | — | — | EP | disclosed |
| CN-113347970-A | Compounds and compositions for treating conditions associated with NLRP activity | 诺华股份有限公司 | 2021-09-03 | — | — | CN | disclosed |
| CN-111417622-A | Sulfonamides and compositions thereof for the treatment of conditions associated with N L RP activity | 诺华炎症研究公司 | 2020-07-14 | — | — | CN | disclosed |
| WO-2019079119-A1 | SULPHONAMIDES AND COMPOSITIONS THEREOF FOR TREATING CONDITIONS ASSOCIATED WITH NLRP ACTIVITY | IFM Tre, Inc. (US) | 2019-04-25 | — | — | WO | disclosed |
| US-20190119241-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH NLRP ACTIVITY | NOVARTIS AG (CH) | 2019-04-25 | — | — | US | disclosed |
| US-20190119241-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH NLRP ACTIVITY | NOVARTIS AG (CH) | 2019-04-25 | — | — | US | disclosed |
| WO-2017184604-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH NLRP ACTIVITY | IFM THERAPEUTICS, INC (US) | 2017-10-26 | — | — | WO | disclosed |
| WO-2017184604-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH NLRP ACTIVITY | IFM THERAPEUTICS, INC (US) | 2017-10-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220387397-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH NLRP ACTIVITY | NLRP1, NLRP3, NOD1 | HDAC8 776/4885CYP17A1 716/4885CYP3A4 2776/4885 |
| US-20220340591-A1 | SULPHONAMIDES AND COMPOSITIONS THEREOF FOR TREATING CONDITIONS ASSOCIATED WITH NLRP ACTIVITY | NLRP1, NLRP3, NOD1 | HDAC8 823/4885CYP17A1 1023/4885CYP3A4 1372/4885 |
| US-11718631-B2 | Sulphonamides and compositions thereof for treating conditions associated with NLRP activity | NLRP1, NLRP3, NOD1 | HDAC8 823/4885CYP17A1 1023/4885CYP3A4 1372/4885 |
| US-20190119241-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH NLRP ACTIVITY | NLRP1, NLRP3, NOD1 | HDAC8 974/4885CYP17A1 853/4885CYP3A4 2816/4885 |
| US-11447460-B2 | Compounds and compositions for treating conditions associated with NLRP activity | NLRP1, NLRP3, NOD1 | HDAC8 810/4885CYP17A1 760/4885CYP3A4 2825/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.